Overexpression of P-glycoprotein, encoded by the MDR1 gene, confers multidrug resistance (MDR) on cancer cells and is a frequent impediment to successful chemotherapy. Recent developments in the use of small interfering RNAs to inhibit specific protein expression have highlighted their potential use as therapeutic agents. We have expressed two different short hairpin RNAs from stably integrated plasmids in doxorubicin-resistant K562 leukaemic cells. The MDR1-targeted RNA interference (RNAi) resulted in decreased MDR1 mRNA, abolished P-glycoprotein expression, and completely reversed the MDR phenotype to that of the drug-sensitive K562 parental line. This study demonstrates that MDR, which is solely due to overexpression of P-glycoprotein, can be reversed by RNAi. These target sequences can in the future be integrated into gene therapy vectors with potential clinical application.
1
P-glycoprotein is a member of the ATP-binding cassette (ABC) superfamily of active transporters and functions by effluxing drugs, reducing their intracellular concentrations and hence, their toxicity. Most efforts at reversing MDR during the past two decades have been to develop compounds that modulate P-glycoprotein activity, such as dexverapamil, dexniguldipine or the cyclosporine D analogue PSC833. In clinical trials, the efficacy of these drugs has been difficult to assess, mainly because of inherent adverse pharmacokinetic side effects. 1 An alternative strategy has been to prevent synthesis of P-glycoprotein at key regulatory steps in its genesis. The transcription inhibitor Ecteinascidin 743 has shown promise in preclinical studies 2 while modulation of the orphan nuclear receptor SXR 3 and the raf-MAPK pathway 4 have also been studied. At the post-transcriptional level, the introduction of antisense oligonucleotides, 5 transcriptional decoys 6 and hammerhead ribozymes 7 have all shown potential at modulating P-glycoprotein-dependent MDR.
RNA interference (RNAi) is a conserved cellular mechanism where double-stranded RNA silences the corresponding homologous cellular gene. 8 Two major discoveries have highlighted its potential application in gene therapy: the introduction of synthetic small interfering RNA (siRNA) of 21 nucleotides into mammalian cells resulted in efficient gene silencing, 9 and short hairpin RNAs (shRNAs) expressed from RNA promoters within expression vectors also triggered RNAi. 10, 11 Recently, modulation of MDR by transient expression of MDR1-targeted siRNAs has been reported. 12, 13 However, in neither study was complete reversal to the drugsensitive phenotype of the parental cells obtained. This was probably due to a combination of biological and technical reasons. First, both groups used cell lines that were extremely resistant to cytotoxic drugs (1-10 mM doxorubicin and 5 mM daunorubicin), derived either from stepwise selection to increasing concentration of drug or the stable expression of MDR1 cDNAs from powerful viral promoters. 14, 15 These cell lines overexpress MDR1 mRNA and P-glycoprotein at much greater levels than those that are clinically relevant. 16 Second, the combined effects of the short duration of RNAi from introduced synthetic siRNAs, and a long protein half-life (14-17 h for P-glycoprotein) 17 resulted in only a partial reduction of P-glycoprotein and MDR.
To mimic more naturally MDR in the clinic, we used a K562 leukemic cell derivative, generated by a single-step selection to a very low concentration of drug, equivalent to that found in the plasma of leukaemia patients 18 (KD30: 30 nM doxorubicin). 19 In addition, stable expression of MDR1 shRNAs targeting different regions of the coding sequence was used, as it has been shown that RNAi is more effective against long-lived proteins from vectors that permit sustained expression than from synthetic siRNA. 20 Two different shRNAs were selected because not all siRNA target sequences are equally potent, 21 to confirm that any silencing observed was gene-specific, 22 and because the MDR1 target sequences of the synthetic siRNA described contained a stretch of four adenines. 12, 13 Premature termination of transcription has been associated with stretches of four or more adenines or thymines, 23 suggesting that these sequences would be unsuitable for vector-based shRNA expression. The two shRNAs selected, which target the MDR1 mRNA at bases 3495-3514 and 586-606, were cloned into the expression vector pSUPER 10 and used to generate stable pools of expressing clones of the previously described doxorubicin-resistant K562 subline, KD30. 19 On average, the pools of clones contained between six and eight copies of the pSUPER transgene (Figure 1 ). Stable expression of siRNAs from the integrated vectors was confirmed by Northern blot analysis (Figure 2 ). Realtime RT-PCR was used to quantify the RNAi-mediated decrease of MDR1 mRNA (Figure 3 ). Expression of MDR1sh1 or MDR1sh2 in KD30 cells reduced MDR1 mRNA by 97 and 95%, respectively ( Figure 3) . The residual MDR1 mRNA in MDR1sh1-and MDR1sh2-expressing KD30 cells was probably due to transgene deletion, silencing by position of integration effects or Figure 1 Integration of pSUPER transgenes into KD30 cells. Cell culture of the K562 drug-sensitive parental line, and the establishment and maintenance of a doxorubicin-resistant (KD30) subline, was as described previously 19 except that the foetal calf serum concentration in the growth medium was reduced to 5%. Design of MDR1 siRNA target sequences was according to recommendations (http://sirna.qiagen.com and http:// www.oligoengine.com). Two sequences, MDR1sh1: 5 0 -AAG GCC TAA TGC CGA ACA CA-3 0 and MDR1sh2: 5 0 -AAC TTT GGC TGC CAT CAT CCA-3 0 , corresponding to bases 3495-3514 and 586-606 respectively, in the MDR1 mRNA sequence (accession number: M14758) were selected. In addition, an irrelevant sequence, control sh: 5 0 -AAT TGG ACA AAC TAC CTA CAG-3 0 , designed to target the SV40 small T antigen mRNA (which is not expressed in KD30 cells) was also selected. These sequences were each incorporated into a pair of oligonucleotides where the target sequence appears as sense followed by antisense orientations separated by a nine nucleotide spacer sequence and flanked at either end by BglII and HindIII restriction enzyme sites. The annealed oligonucleotides were cloned in pSUPER, 10 to generate MDR1sh1, MDR1sh2 and control sh, respectively. Transfection into KD30 cells (1 Â 10 7 ) was by electroporation using a BioRad Gene Pulser (Hercules, CA, USA) at settings of 0.25 kV and 960 mF, with a total of 60 mg DraIII linearized DNAs consisting of a 6:1 molar ratio of pSUPER containing vector to pCIneo (Promega, Madison, WI, USA). Selection for stable pools of greater than 200 cotransfected clones was with G418 (500 mg/ml) and in the absence of doxorubicin. Genomic DNA was isolated and Southern blotting was as described. 19 DNA was double-digested with EcoRI and AflIII and the hybridization was derived from the H1 promoter was obtained by PCR amplification of pSUPER with T7 and T3 primers. Transgene copy number determination was obtained by quantification of hybridization signals of the endogenous to pSUPER-derived H1 promoter sequences, using a PhosphorImager. 0 . The cycling conditions and calculation for relative MDR1 expression levels by the comparative C T method were all as described previously. 19 The MDR1/GAPDH mRNA expression ratio in KD30 cells was set at 100%. Table 1 ). In addition, the relative abundance of RNAs used to normalize MDR1 expression, GAPDH, 18S ribosomal RNA and TBP, was constant in all samples (data not shown).
The effect of the MDR1 RNAi on P-glycoprotein expression was determined by measuring cell surface P-glycoprotein by flow cytometry (Figure 4 ). Drugsensitive parental K562 cells do not express P-glycoprotein, and the peaks of fluorescence of the IgG isotype control and the P-glycoprotein antibody 4E3 overlap. Greater than 92% of KD30 cells express P-glycoprotein with a mean fluorescence value of 114 (Table 1) . In KD30 cells expressing either no shRNA or an irrelevant shRNA from pSUPER (KD30 v and KD30 control sh), the percentage of P-glycoprotein positive cells and their mean fluorescence values remained unchanged. Pglycoprotein expression was almost completely abolished in MDR1sh1-and MDR1sh2-expressing KD30 cells. The percentage decrease of MDR1 mRNA expression in the empty pSUPER vector (v), MDR1sh1-, MDR1sh2-and control sh-expressing KD30 cells was calculated with respect to that for KD30 cells (Figure 3) . Flow cytometric analysis of surface Pglycoprotein expression was carried out as described previously. 19 Both the P-gp-specific antibody (4E3), and the IgG2a isotype control were used at a concentration of 1 mg/1 Â 10 6 cells as recommended. For detection, a phycoerythrin-conjugated goat antimouse IgG secondary antibody was used at a concentration of 0.25 mg/1 Â 10 6 cells. All antibodies were from Dako (Ely, UK). Drug-sensitive K562 cells do not express P-glycoprotein and the IgG (clear) and 4E3 (filled) peaks overlapped. Untransfected KD30, empty vector only cells (KD30 v) and cells expressing an irrelevant shRNA (KD30 control sh) all bind the anti-P-glycoprotein antibody. Expression of MDR1-targeted hairpins (KD30 MDR1sh1 and KD30 MDR1sh2) resulted in loss of P-glycoprotein and the fluorescence returned to levels equal to that of K562.The marker bar (M1) was set to indicate the 0.5% of IgG-labelled cells with the highest fluorescence. Figure 5 Complete reversal of doxorubicin resistance in KD30 cells by MDR1sh1-and MDR1sh2-mediated RNAi. Drug toxicity was determined by a cell proliferation assay and was performed on cells 30-35 days after the initial transfections. In all, 1000 cells per well were seeded in 96-well/ plates to which were added a doxorubicin dilution series in quadruplicate and incubated for 4 days under standard culture conditions. Cell viability was assessed using Celltitre 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA). A volume of 20 ml of the detection solution were added to each well and incubated for 90 min before measuring absorbance at 490 nm on a plate reader (Spectra Max, Molecular Devices Corporation, Sunnyvale, CA, USA). The IC 50 values were defined as the concentration of drug resulting in 50% survival of the treated cells compared to cells grown in the absence of drug. To determine the IC 50 values, the proliferation of cells grown drug-free was set at 100%. Expression of MDR1sh1 and MDR1sh2 in KD30 reversed the drug resistance to levels comparable to those of naïve K562 cells. The results are the representative of at least three experiments. Error bars show s.e.
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E Yagüe et al A small percentage of cells in MDR1sh-expressing pools continued to express low levels of P-glycoprotein ( Figure  4 and Table 1 ). This was probably due to similar reasons as for the residual MDR1 mRNA in MDR1sh-expressing cells discussed previously.
The effect of MDR1 RNAi on MDR was assessed by comparison of IC 50 values using a cell proliferation assay ( Figure 5 and Table 1 ). All cell lines were exposed for 4 days to a dilution series of three different cytotoxic drugs: doxorubicin, colchicine and paclitaxel. All these compounds are transported by P-glycoprotein but they have different mechanisms of action. KD30 cells are 42.5-, 5.7-and 106.7-fold more resistant than the parental K562 line to doxorubicin, colchicine and paclitaxel, respectively. Expression of a control shRNA or transfection with the empty vector (KD30 control sh and KD30 v) had no effect on MDR. In contrast, expression of MDR1sh1 and MDR1sh2 in KD30 cells restored drug sensitivity to levels equal to that of the parental line ( Figure 5 and Table 1) .
Recently, Ramachandran and Wellham 24 used antisense phosphorothiate oligonucleotides to partially sensitize MDR human tumor cells to doxorubicin in mice. The incomplete reversal of the MDR phenotype in their system was probably due to same limitations as when using synthetic siRNAs: short-term repression of the mRNA by the phosphorothiate oligonucleotides and a long P-glycoprotein half-life. The use of shRNAmediated RNAi for MDR1 would overcome these problems and could be incorporated into gene therapy vectors. Lentiviral vectors probably offer the most promise in future preclinical studies. 25 Effective shRNA-mediated gene silencing of targeted genes with these types of vectors has been demonstrated in cycling, noncycling, primary immune, embryonic stem cells and transgenic mice. 26, 27 Drug resistance is believed to arise from multiple mechanisms (increased drug efflux or decreased influx by transporters, activation of detoxifying systems, activation of DNA repair systems and evasion of apoptosis) which may operate singly or in concert. 1 Although several different mechanisms contribute to drug resistance in leukaemia, the most frequent is overexpression of P-glycoprotein. 28, 29 This proof-of-principle study confirms that in a leukaemic cell model system, where MDR is mediated only through Pglycoprotein expression, MDR1 RNAi can completely restore the drug-sensitive phenotype. In chronic myelogenous leukaemia, which is caused by a translocation originating a Bcr-Abl fusion gene, 30 the competitive inhibitor of the Bcr-Abl protein tyrosine kinase, imatinab mesylate (Gleevec or STI-571), has been highly effective in the treatment of patients. 31, 32 However, STI-571-resistant relapse has recently emerged as a significant problem. 33 Although a major cause of resistance appears to be a point mutation in the kinase domain of the target enzyme, P-glycoprotein-mediated resistance has also been implicated. 33, 34 Inhibition of Bcr-Abl expression by transient expression of synthetic siRNA resensitized STI-571-resistant leukaemic cell lines. 35 Therefore, the development of lentiviral vectors targeting Bcr-Abl, 36 MDR1, or other STI-571 resistance-associated genes, 37 to be used singly or in 0 combination therapies 0 represents a novel approach for the treatment of leukaemia.
